Moleculin Biotech Announces Its Miracle Trial Reports 37% Blinded Complete Remission In Venetoclax-failed R/R AML Patients

Benzinga Newsdesk www.benzinga.com Neutral 92.9%

Neg 0% Neu 92.9% Pos 0%

https://www.sec.gov/ix?doc=/Archives/edgar/data/1659617/000143774926025167/mbrx20260729_8k.htm

Comments

No comments yet. Be the first!